Université de Strasbourg

Bertrand Séraphin

Bertrand SéraphinBertrand Séraphin is currently the director of the IGBMC. After a PhD thesis in France and a post-doctoral training in he group of M. Rosbash (Brandeis University, USA), Bertrand Séraphin developed a research group at EMBL working on the mechanism of pre-mRNA splicing. In 2000, he moved to the CGM as head of the RNA department before joining IGBMC in 2009. His group is recognized as a world leader in the analysis of the regulation of gene expression at the post-transcriptional level. Key publications relate to the discovery of new splicing complexes, definition of the mechanism of spliceosome activity, identification of enzymes mediating RNA decay, the discovery of a new cellular compartment implicated in RNA decay and, in collaboration with A. Jacquier and D. Libri, the identification of new eukaryotic transcripts. As a result of the development of the TAP method is also well-known as an international leader in the field of proteomic and protein complex characterization. This part of his research work leads him to become a scientific founder of a Biotech company: Cellzome (Germany). His scientific production has a strong impact as evidence by over 120 papers published in high impact journals referenced in PubMed and a H factor of 47. He has received numerous national and international awards including being Nominated Inventor of the Year 2008 by the European Patent Office, the CNRS Silver Medal in 2007, the Pierce prize of the International Society for Molecular Recognition (2005). He was elected EMBO Member in 2000. He also received the Emilia Valori Prize of the Académie des Sciences in 2014.

As part of his fellowship, Bertrand Séraphin is working on the project Molecular contribution of the DIS3 and SKIV2L mRNA decay factors to development and pathologies in a mammalian model organism.

Investissements d'Avenir